Mirxes is an RNA technology company that develops blood-based miRNA test kits for early disease detection.
Mirxes has raised $91.1M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in January 2026.
Mirxes's investors include Agency for Science, Technology and Research, Rock Springs Capital, Charoen Pokphand Group, EDBI, Mitsui & Co.
Mirxes is headquartered in Singapore, Singapore.
Mirxes is an RNA technology company that develops blood-based miRNA test kits for early disease detection.
Mirxes is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Mirxes — Funding & Investors." VCBacked, January 29, 2026, https://www.vcbacked.co/company/mirxes. Accessed October 1, 2026.
VCBacked. (2026). Mirxes — Funding & Investors. Retrieved October 1, 2026, from https://www.vcbacked.co/company/mirxes
{{cite web |title=Mirxes — Funding & Investors |url=https://www.vcbacked.co/company/mirxes |website=VCBacked |access-date=October 1, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated